Department of Internal Medicine, Gulhane Medical Academy , Ankara , Turkey.
Clin Exp Hypertens. 2013;35(7):516-22. doi: 10.3109/10641963.2012.758734. Epub 2013 Jan 4.
High levels of circulating Von Willebrand factor (vWf) and increased neutrophil to lymphocyte (N/L) ratio may reflect vascular inflammation in hypertensive patients. In present study, we aimed to investigate the effects of valsartan as an angiotensin II receptor antagonist and amlodipine as a calcium channel blocker on the vWf levels and N/L ratio in patients with essential hypertension. Patients were randomized to one of the following intervention protocols: calcium channel blocker (amlodipine, 5-10 mg/day) as group A (n = 20 mean age = 51.85 ± 11.32 y) and angiotensine II receptor blocker (valsartan, 80-320 mg/day) as group B (n = 26 mean age = 49.12 ± 14.12 y). Endothelial dysfunction and vascular inflammation were evaluated with vWf levels and N/L ratio in hypertensive patients before treatment and after treatment in the 12th week. No statistically significant differences were found among the groups in terms of age, sex, and body mass index (BMI). There was a significant decrease in vWf levels (P < .001) and N/L ratio after treatment (P = .04, P < .001, respectively) in both the groups. Von Willebrand factor levels and N/L ratio are very important markers having a role in vascular inflammation and antihypertensive treatment with amlodipine and valsartan may improve cardiovascular outcomes by decreasing these biomarkers.
循环血管性血友病因子（vWf）水平升高和中性粒细胞与淋巴细胞比值（N/L）增加可能反映高血压患者的血管炎症。在本研究中，我们旨在研究血管紧张素 II 受体拮抗剂缬沙坦和钙通道阻滞剂氨氯地平对原发性高血压患者 vWf 水平和 N/L 比值的影响。患者随机分为以下干预方案之一：钙通道阻滞剂（氨氯地平，5-10mg/天）为 A 组（n=20，平均年龄 51.85±11.32 岁）和血管紧张素 II 受体阻滞剂（缬沙坦，80-320mg/天）为 B 组（n=26，平均年龄 49.12±14.12 岁）。在治疗前和治疗后 12 周，通过 vWf 水平和 N/L 比值评估高血压患者的内皮功能障碍和血管炎症。在年龄、性别和体重指数（BMI）方面，各组之间无统计学差异。两组患者的 vWf 水平（P<.001）和 N/L 比值（P=0.04，P<.001）在治疗后均显著降低。vWf 水平和 N/L 比值是血管炎症的重要标志物，氨氯地平和缬沙坦的降压治疗可能通过降低这些生物标志物来改善心血管结局。
